59 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
GLPG Galapagos NV $115.62 $5.94B N/A
Article Searches
Here's Why Galapagos Stock Rose 20.5% in October https://www.fool.com/investing/2019/11/07/heres-why-galapagos-rose-205-in-october.aspx?source=iedfolrf0000001 Nov 07, 2019 - The company reported third-quarter 2019 operating results and deepened its relationship with Gilead Sciences.
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4299307-galapagos-nv-glpg-ceo-onno-van-de-stolpe-q3-2019-results-earnings-call-transcript?source=feed_sector_healthcare Oct 25, 2019 - Galapagos NV (NASDAQ:GLPG) Q3 2019 Results Conference Call October 25, 2019 08:00 AM ET Company Participants Elizabeth Goodwin - VP, IR Onno van de Stolpe - CEO Bart Filius - COO and CFO Walid Abi-Saa
Galapagos NV (GLPG) Q3 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/10/25/galapagos-nv-glpg-q3-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 Oct 25, 2019 - GLPG earnings call for the period ending September 30, 2019.
Gilead's (GILD) Earnings Miss Estimates in Q3, Sales Beat http://www.zacks.com/stock/news/584147/gileads-gild-earnings-miss-estimates-in-q3-sales-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-584147 Oct 25, 2019 - Gilead (GILD) falls short of earnings estimates but marginally beats on sales in the third quarter of 2019.
Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan http://www.zacks.com/stock/news/556224/gilead-gild-files-nda-for-ra-candidate-filgotinib-in-japan?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-556224 Oct 09, 2019 - Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4257576-galapagos-nv-glpg-ceo-onno-van-de-stolpe-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare Apr 28, 2019 - Galapagos NV (NASDAQ:GLPG) Q1 2019 Results Earnings Conference Call April 26, 2019 08:00 AM ET Company Participants Elizabeth Goodwin - VP of IR & Corporate Communications Onno van de Stolpe - Chi
Galapagos NV (GLPG) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/04/26/galapagos-nv-glpg-q1-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 Apr 26, 2019 - GLPG earnings call for the period ending March 31, 2019.
Gilead Files sNDA for Label Expansion of HIV Therapy Descovy http://www.zacks.com/stock/news/372671/gilead-files-snda-for-label-expansion-of-hiv-therapy-descovy?cid=CS-ZC-FT-372671 Apr 08, 2019 - Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.
2 Incredibly Cheap Pharma Stocks to Buy Now https://www.fool.com/investing/2019/04/01/2-incredibly-cheap-pharma-stocks-to-buy-now.aspx?source=iedfolrf0000001 Apr 01, 2019 - Shares of Gilead Sciences and Teva Pharmaceutical Industries are bargains right now.
Gilead & Galapagos Announce Positive Data on Arthritis Drug http://www.zacks.com/stock/news/366666/gilead-galapagos-announce-positive-data-on-arthritis-drug?cid=CS-ZC-FT-366666 Mar 29, 2019 - Gilead (GILD) and partner Galapagos announce positive results from late-stage studies on investigational drug, filgotinib for the treatment of RA.

Pages: 123456

Page 1>